Fermer le menu
The IMPACT2AMR consortium combines the complementary expertise of three highly experienced partners, BioVersys, BioSystems Technology, and Voxcan , to develop novel translational research tools.
The consortium aims to generate a translational research platform to promote the development of antimicrobials and anti-virulence drugs – from the bench to in vivo proof-of-concept.